Preventing the spread of alzheimer’s disease neuropathology: A role for calcilytics?

Current Pharmaceutical Biotechnology

Volumn 16, Issue 8, 2015, Pages 696-706

  Chiarini, Anna ^a   Gardenal, Emanuela ^a   Whitfield, James F ^b   Chakravarthy, Balu ^b   Armato, Ubaldo ^a   Dal Prà, Ilaria ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Alzheimer; Astrocyte; A oligomers; Calcilytics; CaSR; Human; Neuron; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN [1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE 1; CALCILYTIC; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM SENSING RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN; TAU PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; CALCIUM; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CELL MEMBRANE; DNA TRANSCRIPTION; ENZYME ACTIVITY; GENE; GENE OVEREXPRESSION; HUMAN; INTRACELLULAR SIGNALING; LATERAL ENTORHINAL CORTEX; MITOCHONDRION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; ANIMAL; METABOLISM; PATHOLOGY;

FORMICIDAE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASTROCYTES; CALCIUM; HUMANS; TAU PROTEINS;

EID: 84931837203     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201016666150505123813     Document Type: Article

References (119)

1. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimer's Dement., 2012, 8(2), 131-168.
2. Selkoe, D.J. Biochemistry and molecular biology of amyloid betaprotein and the mechanism of Alzheimer's disease. Handb. Clin. Neurol., 2008, 89, 245-260.
3. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356. Erratum in: Science, 2002, 297(5590), 2209.
4. Armstrong, R.A. Spatial pattern of [[amyloid (Aβ) deposits in familial and sporadic Alzheimer's disease. Folia Neuropathol., 2011, 49(3), 153-161.
5. Benzinger, T.L.; Blazey, T.; Jack, C.R. Jr; Koeppe, R.A.; Su, Y.; Xiong, C.; Raichle, M.E.; Snyder, A.Z.; Ances, B.M.; Bateman, R.J.; Cairns, N.J.; Fagan, A.M.; Goate, A.; Marcus, D.S.; Aisen, P.S.; Christensen, J.J.; Ercole, L.; Hornbeck, R.C.; Farrar, A.M.; Aldea, P.; Jasielec, M.S.; Owen, C.J.; Xie, X.; Mayeux, R.; Brickman, A.; McDade, E.; Klunk, W.; Mathis, C.A.; Ringman, J.; Thompson, P.M.; Ghetti, B.; Saykin, A.J.; Sperling, R.A.; Johnson, K.A.; Salloway, S.; Correia, S.; Schofield, P.R.; Masters, C.L.; Rowe, C.; Villemagne, V.L.; Martins, R.; Ourselin, S.; Rossor, M.N.; Fox, N.C.; Cash, D.M.; Weiner, M.W.; Holtzman, D.M.; Buckles, V.D.; Moulder, K.; Morris, J.C. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2013, 110(47), E4502-4509.
6. Domert, J.; Rao, S.B.; Agholme, L.; Brorsson, A.C.; Marcusson, J.; Hallbeck, M.; Nath, S. Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol. Dis., 2014, 65, 82-92.
7. Braak, H.; Braak, E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol., 1991, 1(3), 213-216.
8. Nordberg, A. Dementia in 2014. Towards early diagnosis in Alzheimer disease. Nat. Rev. Neurol., 2015, 11(2), 69-70.
9. Khan, U.A.; Liu, L.; Provenzano, F.A.; Berman, D.E.; Profaci, C.P.; Sloan, R.; Mayeux, R., Duff, K.E.; Small, S.A. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci, 2014, 17(2), 304- 311.
10. Gómez-Isla, T.; Price, J.L.; McKeel, D.W. Jr; Morris, J.C.; Growdon, J.H.; Hyman, B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci., 1996, 16(14), 4491-4500.
11. West, M.J.; Kawas, C.H.; Stewart, W.F.; Rudow, G.L.; Troncoso, J.C. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol. Aging., 2004, 25(9), 1205-1212.
12. Sperling, R.A.; Aisen, P.S.; Beckett, L.A.; Bennett, D.A.; Craft, S.; Fagan, A.M.; Iwatsubo, T.; Jack, C.R. Jr; Kaye, J.; Montine, T.J.; Park, D.C.; Reiman, E.M.; Rowe, C.C.; Siemers, E.; Stern, Y.; Yaffe, K.; Carrillo, M.C.; Thies, B.; Morrison-Bogorad, M.; Wagster, M.V.; Phelps, CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement., 2011, 7(3), 280-292.
13. Dal Prà, I.; Chiarini, A.; Gui, L.; Chakravarthy, B.; Pacchiana, R.; Gardenal, E.; Whitfield, J.F.; Armato, U. Do astrocytes collaborate with neurons in spreading the "infectious" Aβ and Tau drivers of Alzheimer's disease? Neuroscientist, 2015, 21(1), 9-29.
14. Klemm, W.R. "Mental Biology: The New Science of How the Brain and Mind Relate". Prometheus Books, Amherst, NY, 2014.
15. Puzzo, D.; Privitera, L.; Leznik, E.; Fà, M.; Staniszewski, A.; Palmeri, A.; Arancio, O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci., 2008, 28(53), 14537-14545.
16. Puzzo, D.; Privitera, L.; Fa', M.; Staniszewski, A.; Hashimoto, G.; Aziz, F.; Sakurai, M.;Ribe, E.M.; Troy, C.M.; Mercken, M.; Jung, S.S.; Palmeri, A.; Arancio, O. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol., 2011, 69(5), 819-830.
17. Barucker, C.; Sommer, A.; Beckmann, G.; Eravci, M.; Harmeier, A.; Schipke, C.G.; Brockschnieder, D.; Dyrks, T.; Althoff, V.; Fraser, P.E.; Hazrati, L.N.; George-Hyslop, P.S.; Breitner, J.C.; Peters, O.; Multhaup, G. Alzheimer Amyloid Peptide Aβ42 Regulates Gene Expression of Transcription and Growth Factors. J. Alzheimers Dis., 2015, 44(2), 613-624.
18. Cárdenas-Aguayo, M. del C.; Silva-Lucero, M. del C.; Cortes- Ortiz, M.; Jiménez-Ramos, B.; Gómez-Virgilio, L.; Ramírez- Rodríguez, G.; Vera- Arroyo, E.; Fiorentino-Pérez, R.; García, U.; Luna-Muñoz, J.; Meraz-Ríos, M.A. Physiological role of amyloid beta in neural cells: The Cellular Trophic Activity. In: Neurochemistry; Heinbockel T., Ed.; InTech: Rijeka, Croatia. doi: 10.5772/57398, 2014.
19. Garcia-Osta, A.; Alberini, C.M. Amyloid beta mediates memory formation. Learn. Mem., 2009, 16(4), 267-272.
20. Koudinov, A.R.; Berezov, T.T. Alzheimer's amyloid-beta (A beta) is an essential synaptic protein, not neurotoxic junk. Acta Neurobiol. Exp. (Wars), 2004, 64(1), 71-79.
21. Morley, J.E.; Farr, S.A.; Banks, W.A.; Johnson, S.N.; Yamada, K.A.; Xu, L. A physiological role for amyloid-beta protein: enhancement of learning and memory. J. Alzheimers Dis., 2010, 19(2), 441-449.
22. Shankar, G.M.; Li, S.; Mehta, T.H.; Garcia-Munoz, A.; Shepardson, N.E.; Smith, I.; Brett, F.M., Farrell, M.A.; Rowan, M.J.; Lemere, C.A.; Regan, C.M.; Walsh, D.M.; Sabatini, B.L.; Selkoe, D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., 2008, 14(8), 837-842.
23. Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Cullen, W.K.; Anwyl, R.; Wolfe, M.S.; Rowan, M.J.; Selkoe, D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal longterm potentiation in vivo. Nature, 2002, 416(6880), 535-539.
24. Roher, A.E.; Ball, M.J.; Bhave, S.V.; Wakade, A.R. Beta-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem. Biophys. Res. Commun., 1991, 174(2), 572-579.
25. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L.; Wals, P.; Zhang, C.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 1998, 95(11), 6448-6453.
26. Chiarini, A.; Dal Prà, I.; Menapace, L.; Pacchiana, R.; Whitfield, J.F.; Armato, U. Soluble amyloid beta-peptide and myelin basic protein strongly stimulate, alone and in synergism with combined proinflammatory cytokines, the expression of functional nitric oxide synthase-2 in normal adult human astrocytes. Int. J. Mol. Med., 2005, 16(5), 801-807.
27. Sanchez, A.; Tripathy, D.; Luo, J.; Yin, X.; Martinez, J.; Grammas, P. Neurovascular unit and the effects of dosage in VEGF toxicity: role for oxidative stress and thrombin. J. Alzheimers Dis., 2013, 34(1), 281-291.
28. Peng, L.; Parpura, V.; Verkhratsky, A. Editorial. Neuroglia as a central element of neurological diseases: An underappreciated tar get for therapeutic intervention. Curr. Neuropharmacol., 2014, 12(4), 303-307.
29. Rossner, S.; Lange-Dohna, C.; Zeitschel, U.; Perez-Polo, J.R. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. J. Neurochem., 2005, 92(2), 226-234.
30. Dal Prà, I.; Whitfileld, J.F.; Pacchiana, R.; Bonafini, C.; Talacchi, A.; Chakravarthy, B.; Armato, U.; Chiarini, A. The amyloid-β(42) proxy, amyloid-β(25-35), induces normal human cerebral astrocytes to produce amyloid-β(42). J. Alzheimers Dis., 2011, 24(2), 335-347.
31. Attems, J.; Thal, D.R.; Jellinger, K.A. The relationship between subcortical tau pathology and Alzheimer's disease. Biochem. Soc. Trans., 2012, 40(4), 711-715.
32. Braak, H.; Del Tredici, K. Evolutional aspects of Alzheimer's disease pathogenesis. J. Alzheimer's Dis., 2013, 33(Suppl. 1), S155-161.
33. Braak, H.; Zetterberg, H.; Del Tredici, K.; Blennow, K. Intraneuronal Tau aggregation precedes diffuse plaque deposition, but amyloid- β changes occur before increases of Tau in cerebrospinal fluid. J. Alzheimer's Dis., 2013, 33(Suppl.1), S67-78.
34. Murray, M.E.; Lowe, V.J.; Graff-Radford, N.R.; Liesinger, A.M.; Cannon, A.; Przybelski, S.A.; Rawal, B.; Parisi, J.E.; Petersen, R.C.; Kantarci, K.; Ross, O.A.; Duara, R.; Knopman, D.S.; Jack, C.R. Jr; Dickson, D.W. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain, 2015 Mar 23. pii: awv050.
35. Thal, D.R.; Rub, U.; Orantes, M.; Braak, H. Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology, 2002, 58, 1791-1800.
36. Bennett, D.A.; Schneider, J.A.; Wilson, R.S.; Bienias, J.L.; Arnold, S.E. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol., 2004, 61, 378-84.
37. Nelson, P.T.; Alafuzoff, I.; Bigio, E.H.; Bouras, C.; Braak, H.; Cairns, N.J.; Castellani, R.J.; Crain, B.J.; Davies, P.; Del Tredici, K.; Duyckaerts, C.; Frosch, M.P.; Haroutunian, V.; Hof, P.R.; Hulette, C.M.; Hyman, B.T.; Iwatsubo, T.; Jellinger, K.A.; Jicha, G.A.; Kövari, E.; Kukull, W.A.; Leverenz, J.B.; Love, S.; Mackenzie, I.R.; Mann, D.M.; Masliah, E.; McKee, A.C.; Montine, T.J.; Morris, J.C.; Schneider, J.A.; Sonnen, J.A.; Thal, D.R.; Trojanowski, J.Q.; Troncoso, J.C.; Wisniewski, T.; Woltjer, R.L.; Beach, T.G. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol., 2012, 71(5), 362-81.
38. Fornicola, W.; Pelcovits, A.; Li, B.X.; Heath, J.; Perry, G.; Castellani, R.J. Alzheimer disease pathology in middle age reveals a spatial- temporal disconnect between amyloid-β and phosphorylated tau. Open Neurol. J., 2014, 8, 22-26.
39. Choi, S.H.; Kim, Y.H.; Hebisch, M.; Sliwinski, C.; Lee, S.; D'Avanzo, C.; Chen, H.; Hooli, B.; Asselin, C.; Muffat, J.; Klee, J.B.; Zhang, C.; Wainger, B.J.; Peitz, M.; Kovacs, D.M.; Woolf, C.J.; Wagner, S.L.; Tanzi, R.E.; Kim, D.Y. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature, 2014, 515(7526), 274-278.
40. Crimins, J.L.; Pooler, A.; Polydoro, M.; Luebke, J.I.; Spires-Jones, T.L. The intersection of amyloid beta and Tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res. Revs., 2013, 12, 757-763.
41. Kayed, R.; Lasagna-Reeves, C.A. Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis., 2013, 33(Suppl. 1), S67-78.
42. Klein, W.L. Synaptotoxic amyloid-β oligomers: A molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J. Alzheimer's Dis., 2013, 33(Suppl 1), S49-S65.
43. Brettschneider, J.; Del Tredici, K.; Lee, V.M.; Trojanowski, J.Q. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat. Rev. Neurosci., 2015, 16(2), 109-120.
44. Maloney, B.; Lahiri, D.K. The Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: Characterizing a new regulatory motif. Gene, 2011, 488(1-2), 1-12.
45. Barucker, C.; Harmeier, A.; Weiske, J.; Fauler, B.; Albring, K.F.; Prokop, S.; Hildebrand, P.; Lurz, R.; Heppner, F.L.; Huber, O.; Multhaup, G. Nuclear translocation uncovers the amyloid peptide Aβ42 as a regulator of gene transcription. J. Biol. Chem., 2014, 289(29), 20182-20191.
46. Bailey, A.; Maloney, B.; Ge, Y.W.; Lahiri, D.K. Functional activity of the novel Alzheimer's amyloid β -peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene, 2011, 488(1-2), 13-22.
47. Armato. U.; Chiarini, A.; Chakravarthy, B.; Chioffi, F.; Pacchiana, R.; Colarusso, E.; Whitfield, J.F.; Dal Prà, I. Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Aβ42 prompted by exogenous fibrillary or soluble Aβ25-35 in human cortical astrocytes and neurons- Therapeutic relevance to Alzheimer's disease. Biochim. Biophys. Acta, 2013, 1832(10), 1634-1652.
48. Kinoshita, A.; Fukumoto, H.; Shah, T.; Whelan, C.M.; Irizarry, M.C.; Hyman, B.T. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J. Cell Sci., 2003, 116(Pt 16), 3339-3346.
49. Teng, F.Y.; Tang, B.L. Widespread gamma-secretase activity in the cell, but do we need it at the mitochondria? Biochem. Biophys. Res. Commun., 2005, 328(1), 1-5.
50. Ohyagi, Y.; Yamada, T.; Nishioka, K.; Clarke, N.J.; Tomlinson, A.J.; Naylor, S.; Nakabeppu, Y.; Kira, J.; Younkin, S.G. Selective increase in cellular Abeta42 is related to apoptosis but not necrosis. Neuroreport, 2000, 11(1), 167-171.
51. Chui, D.H.; Dobo, E.; Makifuchi, T.; Akiyama, H.; Kawakatsu, S.; Petit, A.; Checler, F.; Araki, W.; Takahashi, K.; Tabira, T. Apoptotic neurons in Alzheimer's disease frequently show intracellular Abeta42 labeling. J. Alzheimers Dis., 2001, 3(2), 231-239
52. Gouras, G.K.; Tsai, J.; Naslund, J.; Vincent, B.; Edgar, M.; Checler, F.; Greenfield, J.P.; Haroutunian, V.; Buxbaum, J.D.; Xu, H.; Greengard, P.; Relkin, N.R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol., 2000, 156(1), 15-20.
53. Gyure, K.A.; Durham, R.; Stewart, W.F.; Smialek, J.E.; Troncoso, J.C. Intraneuronal beta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med., 2001, 125(4), 489-492.
54. Kimura, N.; Yanagisawa, K.; Terao, K.; Ono, F.; Sakakibara, I.; Ishii, Y.; Kyuwa, S.; Yoshikawa, Y. Age-related changes of intracellular Abeta in Cynomolgus monkey brains. Neuropathol. Appl. Neurobiol., 2005, 31(2), 170-180.
55. Torp, R.; Head, E.; Milgram, N.W.; Hahn, F.; Ottersen, O.P.; Cotman, C.W. Ultrastructural evidence of fibrillar beta-amyloid associated with neuronal membranes in behaviorally characterized aged dog brains. Neuroscience, 2000, 96(3), 495-506.
56. Wang, D.S.; Dickson, D.W.; Malter, J.S. Beta-amyloid degradation and Alzheimer's disease. J. Biomed. Biotechnol., 2006, 2006(3), 58406.
57. López Salon, M.; Pasquini, L.; Besio Moreno, M.; Pasquini, J.M.; Soto, E. Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp. Neurol., 2003, 180(2), 131- 143.
58. López Salon, M.; Morelli, L.; Castaño, E.M.; Soto, E.F.; Pasquini, J.M. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J. Neurosci. Res., 2000, 62(2), 302-310.
59. Hong, L.; Huang, H.C.; Jiang, Z.F. Relationship between amyloidbeta and the ubiquitin-proteasome system in Alzheimer's disease. Neurol. Res., 2014, 36(3), 276-282.
60. Ihara, Y.; Morishima-Kawashima, M.; Nixon, R. The ubiquitinproteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harb. Perspect. Med., 2012, 2(8), pii:a006361.
61. 2+-sensing receptor (CaSR) in the expression of inducible NOS (nitric oxide synthase)-2 and its BH4 (tetrahydrobiopterin)- dependent activation in cytokine-stimulated adult human astrocytes. J. Cell Biochem., 2005, 96(2), 428-438.
62. Cordes, C.M.; Bennett, R.G.; Siford, G.L.; Hamel, F.G. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation. Biochem. Pharmacol., 2009, 77(6), 1064- 1073.
63. Lee, M.J.; Lee, J.H.; Rubinsztein, D.C. Tau degradation: the ubiquitin- proteasome system versus the autophagy-lysosome system. Prog. Neurobiol., 2013, 105, 49-59.
64. Saez, T.E.; Pehar, M., Vargas, M.; Barbeito, L.; Maccioni, R.B. Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In vivo, 2004, 18(3), 275-280.
65. Greengard, P.; Shupliakov, O.; Bobba, A.; Amadoro, G.; Valenti, D.; Corsetti, V.; Lassandro, R.; Atlante, A. Mitochondrial respiratory chain Complexes I and IV are impaired by β-amyloid via direct interaction and through Complex I-dependent ROS production, respectively. Mitochondrion, 2013, 13(4), 298-311.
66. Caldeira, G.L.; Ferreira, I.L.; Rego, A.C. Impaired transcription in Alzheimer's disease: key role in mitochondrial dysfunction and oxidative stress. J. Alzheimers Dis., 2013, 34(1), 115-131.
67. Morawski, M.; Schilling, S.; Kreuzberger, M.; Waniek, A.; Jäger, C.; Koch, B.; Cynis, H.; Kehlen, A.; Arendt, T.; Hartlage- Rübsamen, M.; Demuth, H.U.; Roßner, S. Glutaminyl cyclase in human cortex: Correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease. J. Alzheimers Dis., 2013, 39(2), 385-400.
68. Lee, J.E.; Kang, J.S.; Shin, I.C.; Lee, S.J.; Hyun, D.H.; Lee, K.S.; Koh, H.C. Fluazinam-induced apoptosis of SH-SY5Y cells is mediated by p53 and Bcl-2 family proteins. Neurotoxicology, 2011, 32(6), 702-710.
69. Yano, S.; Brown, E.M.; Chattopadhyay, N. Calcium-sensing receptor in the brain. Cell Calcium, 2004, 35(3), 257-264.
70. Ye, C.; Ho-Pao, C.L.; Kanazirska, M.; Quinn, S.; Rogers, K.; Seidman, C.E.; Seidman, J.G. Amyloid-beta proteins activate Ca(2+)-permeable channels through calcium-sensing receptors. J. Neurosci. Res., 1997, 47(5), 547-554.
71. Conley, Y.P.; Mukherjee, A.; Kammerer, C.; DeKosky, S.T.; Kamboh, M.I.; Finegold, D.N.; Ferrell, R.E. Evidence supporting a role for the calcium-sensing receptor in Alzheimer disease. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2009, 150B(5), 703-709.
72. Ulm, J.W.; Nygaard, H.B.; Heiss, J.K.; Kostylev, M.A.; Stagi, M.; Vortmeyer, A.; Wisniewski, T.; Gunther, E.C.; Strittmatter, S.M. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci., 2012, 15(9), 1227- 1235.
73. Laurén, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature, 2009, 457(7233), 1128-1132.
74. Larson, M.; Sherman, M.A.; Amar, F.; Nuvolone, M.; Schneider, J.A.; Bennett, D.A.; Aguzzi, A.; Lesné, S.E. The complex PrP(c)- Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J. Neurosci., 2012, 32(47), 16857-16871a.
75. Lee, G.; Thangavel, R.; Sharma, V.M.; Litersky, J.M.; Bhaskar, K.; Fang, S.M.; Do, L.H.; Andreadis, A.; Van Hoesen, G.; Ksiezak- Reding, H. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J. Neurosci., 2004, 24(9), 2304-2312.
76. Reynolds, C.H.; Garwood, C.J.; Wray, S.; Price, C.; Kellie, S.; Perera, T.; Zvelebil, M.; Yang, A.; Sheppard, P.W.; Varndell, I.M.; Hanger, D.P.; Anderton, B.H. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3- kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J. Biol. Chem., 2008, 283(26), 18177-18186.
77. Trepanier, C.H.; Jackson, M.F.; MacDonald, J.F. Regulation of NMDA receptors by the tyrosine kinase Fyn. FEBS J., 2012, 279(1), 12-19.
78. Bliss, T.V.; Collingridge, G.L. A synaptic model of memory: longterm potentiation in the hippocampus. Nature, 1993, 361(6407), 31-39.
79. Kornau, H.C.; Schenker, L.T.; Kennedy, M.B.; Seeburg, P.H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science, 1995, 269(5231), 1737- 1740.
80. El-Husseini, A.E.; Schnell, E.; Chetkovich, D.M. Nicoll, R.A., Bredt, D.S. PSD-95 involvement in maturation of excitatory synapses. Science, 2000, 290(5495), 1364-1368.
81. Bhaskar, K.; Yen, S.H.; Lee, G. Disease-related modifications in tau affect the interaction between Fyn and Tau. J. Biol. Chem., 2005, 280(42), 35119-35125.
82. Tu, S.; Okamoto, S.; Lipton, S.A.; Xu, H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease. Mol. Neurodegener., 2014, 9, 48.
83. Chin, J.; Palop, J.J.; Puoliväli, J.; Massaro, C.; Bien-Ly, N.; Gerstein, H.; Scearce-Levie, K.; Masliah, E.; Mucke, L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci., 2005, 25(42), 9694- 9703.
84. Kaufman, A.C.; Salazar, S.V.; Haas, L.T.; Yang, J.; Kostylev, M.A.; Jeng, A.T.; Robinson, S.A.; Gunther, E.C.; van Dyck, C.H.; Nygaard, H.B.; Strittmatter, S.M. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann. Neurol., 2015 Feb 23.doi: 10.1002/ana.24394.
85. Pozueta, J.; Lefort, R.; Shelanski, M.L. Synaptic changes in Alzheimer's disease and its models. Neuroscience, 2013, 251, 51-65.
86. Alonso, A.C.; Li, B.; Grundke-Iqbal, I.; Iqbal, K. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr. Alzheimer Res., 2008, 5(4), 375-384.
87. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J. Alzheimers Dis., 2006, 9(3 Suppl), 309-317.
88. Hanger, D.P.; Byers, H.L.; Wray, S.; Leung, K.Y.; Saxton, M.J.; Seereeram, A.; Reynolds, C.H.; Ward, M.A.; Anderton, B.H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem., 2007, 282(32), 23645-23654.
89. Tavares, I.A.; Touma, D.; Lynham, S.; Troakes, C.; Schober, M.; Causevic, M.; Garg, R.; Noble, W.; Killick, R.; Bodi, I.; Hanger, D.P.; Morris, J.D. Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle- bearing neurons in Alzheimer disease. J. Biol. Chem., 2013, 288(21), 15418-15429.
90. Köpke, E.; Tung, Y.C.; Shaikh, S.; Alonso, A.C.; Iqbal, K.; Grundke-Iqbal, I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem., 1993, 268, 24374-24384.
91. Haas, C.; Mandelkow, E. Fyn-Tau-amyloid: a toxic triad. Cell, 2010, 142, 356-358.
92. Douaud, G.; Menke, R.A.; Gass, A.; Monsch, A.U.; Rao, A.; Whitcher, B.; Zamboni, G.; Matthews, P.M.; Sollberger, M.; Smith, S. Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease. J. Neurosci., 2013, 33(5), 2147-2155.
93. Talantova, M.; Sanz-Blasco, S.; Zhang, X.; Xia, P.; Akhtar, M.W.; Okamoto, S.; Dziewczapolski, G.; Nakamura, T.; Cao, G.; Pratt, A.E.; Kang, Y.J.; Tu, S.; Molokanova, E.; McKercher, S.R.; Hires, S.A.; Sason, H.; Stouffer, D.G.; Buczynski, M.W.; Solomon, J.P.; Michael, S.; Powers, E.T.; Kelly, J.W.; Roberts, A.; Tong, G.; Fang-Newmeyer, T.; Parker, J.; Holland, E.A.; Zhang, D.; Nakanishi, N.; Chen, H.S.; Wolosker, H.; Wang, Y.; Parsons, L.H.; Ambasudhan, R.; Masliah, E.; Heinemann, S.F.; Piña-Crespo, J.C.; Lipton, S.A. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. USA, 2013, 110(27), E2518-2527. Correction in: Proc. Natl. Acad. Sci. USA, 110, 13691.
94. Ye, C.; Ho-Pao, C.L.; Kanazirska, M., Quinn, S.; Rogers, K.; Seidman, C.E.; Seidman, J.G.; Brown, E.M.; Vassilev, P.M. Amyloid- beta proteins activate Ca(2+)-permeable channels through calcium- sensing receptors. J. Neurosci. Res., 1997, 47(5), 547-554.
95. Conley, Y.P.; Mukherjee, A.; Kammerer, C.; DeKosky, S.T.; Kamboh, M.I.; Finegold, D.N.; Ferrell, R.E. Evidence supporting a role for the calcium-sensing receptor in Alzheimer disease. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2009, 150B(5), 703-709.
96. Dal Prà, I.; Armato, U.; Chioffi, F.; Pacchiana, R.; Whitfield, J.F.; Chakravarthy, B.; Gui, L.; Chiarini, A. The Aβ peptides-activated calcium-sensing receptor stimulates the production and secretion of vascular endothelial growth factor-A by normoxic adult human cortical astrocytes. Neuromol. Med., 2014, 16(4), 645-657.
97. Dal Prà, I.; Chiarini, A.; Pacchiana, R.; Gardenal, E.; Chakravarthy, B.; Whitfield, J.F.; Armato, U. Calcium-sensing receptors of human astrocyte-neuron teams: Amyloid-β-driven mediators and therapeutic targets of Alzheimer's disease. Curr. Neuropharmacol., 2014, 12(4), 353-364.
98. Kim, J.Y.; Ho, H.; Kim, N.; Liu, J.; Yenari, M.A.; Wenhan, C. Calcium-sensing receptor (CaSR): a novel target for ischemic neuroprotection. Ann. Clin. Transl. Neurol., 2014, 1(11), 851-866
99. Eisele, Y.S.; Bolmont, T.; Heikenwalder, M.; Langer, F.; Jacobson, L.H.; Yan, Z.X.; Roth, K.; Aguzzi, A.; Staufenbiel, M.; Walker, L.C.; Jucker, M. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc. Natl. Acad. Sci. USA, 2009, 106(31), 12926-12931.
100. Jucker, M.; Walker, L.C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol., 2011, 70(4), 532-540.
101. Rosen, R.F.; Fritz, J.J.; Dooyema, J.; Cintron, A.F.; Hamaguchi, T.; Lah, J.J.; LeVine, H. 3rd; Jucker, M.; Walker, L.C. Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats. J. Neurochem., 2012, 120(5), 660-666.
102. Saman, S.; Kim, W.; Raya, M.; Visnick, Y.; Miro, S.; Saman, S.; Jackson, B.; McKee, A.C.; Alvarez, V.E.; Lee, N.C.; Hall, G.F. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem., 2012, 287(6), 3842-3849.
103. Clavaguera, F.; Bolmont, T.; Crowther, R.A.; Abramowski, D.; Frank, S.; Probst, A.; Fraser, G.; Stalder, A.K.; Beibel, M.; Staufenbiel, M.; Jucker, M.; Goedert, M.; Tolnay, M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol., 2009, 11, 909-913.
104. Clavaguera, F.; Akatsu. H.; Fraser, G.; Crowther, R.A.; Frank, S.; Hench, J.; Probst, A.; Winkler, D.T.; Reichwald, J.; Staufenbiel, M.; Ghetti, B.; Goedert, M.; Tolnay, M. Brain homogenates from human tauopathies induce Tau inclusions in mouse brain. Proc. Natl. Acad. Sci. USA, 2013, 110, 9535-9540.
105. Clavaguera, F.; Lavenir, I.; Falcon, B.; Frank, S.; Goedert, M.; Tolnay, M. "Prion-like" templated misfolding in tauopathies. Brain Pathol., 2013, 23, 342-349.
106. Ferrer, I.; Legati, A.; García-Monco, J.C.; Gomez-Beldarrain, M.; Carmona, M.; Blanco, R.; Seeley, W.W.; Coppola, G. Familial behavioral variant frontotemporal dementia associated with astrocytepredominant tauopathy. J. Neuropathol. Exp. Neurol., 2015, 74(4), 370-379.
107. Morales, R.; Callegari, K.; Soto, C. Prion-like features of misfolded Aβ and tau aggregates. Virus Res., 2015 Jan 6. pii: S0168- 1702(14)00545-0. doi: 10.1016/j.virusres.2014.12.031.
108. Nussbaum, J.M.; Seward, M.E.; Bloom, G.S. Alzheimer disease: a tale of two prions. Prion, 2013, 7(1), 14-19.
109. Moreno-Gonzalez, I.; Soto, C. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin. Cell Dev. Biol., 2011, 22(5), 482-487.
110. Frost, B.; Jacks, R.L.; Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem., 2009, 284(19), 12845-12852.
111. Eisele, Y.S.; Obermüller, U.; Heilbronner, G.; Baumann, F.; Kaeser, S.A.; Wolburg, H.;Walker, L.C.; Staufenbiel, M.; Heikenwalder, M.; Jucker, M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science, 2010, 330(6006), 980-982.
112. Irwin, D.J.; Abrams, J.Y.; Schonberger, L.B.; Leschek, E.W.; Mills, J.L.; Lee, V.M.; Trojanowski, J.Q. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol., 2013, 70(4), 462-468.
113. Aguzzi, A.; Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron, 2009, 64, 783-790.
114. Sanders, D.W.; Kaufman, S.K.; DeVos, S.L.; Sharma, A.M.; Mirbaha, H.; Li, A.; Barker, S.J.; Foley, A.C.; Thorpe, J.R.; Serpell, L.C.; Miller, T.M.; Grinberg, L.T.; Seeley, W.W.; Diamond, M.I. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron, 2014, 82, 1271-1288.
115. Aguzzi, A. Neurodegeneration: Alzheimer's disease under strain. Nature, 2014, 512, 32-34.
116. Nemeth, E.F. The search for calcium receptor antagonists (calcilytics). J.Mol.Endocrinol., 2002, 29(1), 15-21.
117. Nemeth, E.F., Shoback D. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. Best Pract. Res. Clin. Endocrinol. Metab., 2013, 27(3), 373-384.
118. Nemeth, E.F. Allosteric modulators of the extracellular calcium receptor. Drug Discov. Today Technol., 2013, 10(2), e277-284.
119. John, M.R.; Harfst, E.; Loeffler, J.; Belleli, R.; Mason, J.; Bruin, G.J.; Seuwen, K.; Klickstein, L.B.; Mindeholm, L.; Widler, L.; Kneissel, M. AXT914 a novel, orally-active parathyroid hormonereleasing drug in two early studies of healthy volunteers and postmenopausal women. Bone, 2014, 64, 204-210.